New EGA group to promote access to ''value-added'' drugs
This article was originally published in Scrip
The EGA, which represents generics and biosimilars companies in Europe, has set up a new internal group to help increase patient access to value-added off-patent medicines such as those that improve compliance or offer a different delivery route from the originator medicine.
You may also be interested in...
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.
The EU’s massive economic stimulus package, Next Generation EU, includes a wide-ranging health program that aims to make health systems more resilient to future threats by supporting the development and manufacture of affordable new medicines and vaccines as well as measures to prevent drug shortages.